Remove Clinical Development Remove Licensing Remove Science
article thumbnail

Women in STEM with Kristina Torfgard

Drug Target Review

This role gave me a good understanding of how important IP/patent and global marketing are for the brand but also the importance of emerging markets and co-development and out-licensing to other pharma companies. Already, three candidates are in clinical development and the lead candidate is ready to enter Phase III.

article thumbnail

BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES

The Pharma Data

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR. star.edu.sg.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure

The Pharma Data

–( BUSINESS WIRE )– Gilead Sciences, Inc. While HIV treatment has advanced dramatically over the past three decades, people living with HIV still face a lifetime of therapy,” said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. About Gilead Sciences. Gilead Sciences, Inc.

Vaccine 52
article thumbnail

Tauriga Sciences Inc. Funds the Entirety of the Master Services Agreement that it Recently Entered Into with CSTI

The Pharma Data

The Company has Now Resumed the Clinical Development of its Proposed Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum. 24, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences Inc. On December 18, 2020 – The Company issued the following press release: “Tauriga Sciences Inc. Tauriga Sciences, Inc.

Science 52
article thumbnail

Advancing neurological therapies with Dr Bruce Leuchter

Drug Target Review

In other cases, well-established biomarker profiles enable patient enrichment strategies in early-stage clinical development. Neurvati’s model can be characterised as a private equity model for neurotherapeutics development. We were able to license a molecule from a multi-national pharmaceutical company.

Therapies 104
article thumbnail

Enara Bio, Boehringer Ingelheim Agree to Collab on Immunotherapy Discovery Research

The Pharma Data

Boehringer Ingelheim has announced it has signed a collaboration and licensing deal with Enara Bio to advance novel targeted cancer immunotherapies. According to Enara, Dark Antigens can potentially be developed as targets for immunotherapy agents. Michael Vi/Shutterstock.

article thumbnail

South Africa’s mRNA hub progress is foundation for self-reliance

The Pharma Data

Covid-19 has demonstrated the importance of investments in science, technology and innovation. This virus shows how interconnected we all are and I am proud that Belgium –and other EU countries – are now collaborating to build vaccine capacity everywhere,” said Meryame Kitir, Minister of Development Cooperation and Urban Policy of Belgium.

Vaccine 52